Hepion Pharmaceuticals, Inc. Banner Image

Hepion Pharmaceuticals, Inc.

  • Ticker HEPA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Hepion Pharmaceuticals, Inc. Logo Image
  • 11-50 Employees
  • Based in Edison, New Jersey
Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and other types of hepatitis. The Company's lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstratedMore antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431's potent inhibition of cyclophilins, which are involved in many disease processes. Currently in clinical phase development, CRV431 shows potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease.
4.8 / 5.0 (301)

Hepion Pharmaceuticals, Inc. reports have an aggregate usefulness score of 4.8 based on 301 reviews.

Hepion Pharmaceuticals, Inc.

Most Recent Annual Report

Hepion Pharmaceuticals, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Hepion Pharmaceuticals, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!